Nano-X Imaging Ltd. Form 6-K Summary
Business Context and Reporting Period
Nano-X Imaging Ltd., an Israel-based medical imaging technology company, filed this Form 6-K on July 24, 2023, reporting events for July 2023. The filing concerns a registered direct offering and updates on SEC and shareholder litigation matters.
Offering and Key Financial Metrics
- Equity issued: 2,142,858 ordinary shares sold to a single institutional investor.
- Combined purchase price: $14.00 per share together with accompanying warrants.
- Expected gross proceeds: Approximately $30.0 million, before fees and expenses, based on the stated share count and purchase price.
- Warrants: Warrants to purchase up to 2,142,858 ordinary shares, exercisable immediately at $19.00 per share and expiring five years after issuance.
- Potential additional proceeds: Approximately $40.7 million if all warrants are exercised for cash, although the filing provides no assurance that any warrants will be exercised.
- Closing: Expected July 26, 2023, subject to customary closing conditions.
- Cash flow, revenue, profit, margins, debt and liquidity: The filing does not provide operating or balance-sheet results for the period.
Material Changes and Legal Matters
- The company and Chairman Ran Poliakine reached agreements in principle with SEC staff to resolve an investigation concerning, among other matters, development costs of Nanox.ARC prototypes and estimated costs of assembling the product at scale.
- Estimated remedies are approximately $650,000 in civil penalties for the company and less than $500,000 in penalties, disgorgement and prejudgment interest for Mr. Poliakine. Final terms remain subject to documentation, company board approval, SEC authorization and federal court approval.
- The company cannot assure that the SEC settlement will be finalized or approved, or specify the timing or final terms.
- The company entered into an $8 million settlement agreement on June 2, 2023, covering shareholder class-action litigation related to the McLaughlin action and consolidated White action. The settlement remains subject to court approval and other conditions.
- The White action involves alleged securities-law violations concerning disclosures about the company’s FDA submission and customer contracts. The McLaughlin action concerns disclosures regarding Nanox.ARC costs and comparisons with CT scanners. Motions and consolidation or stay requests remained pending as described in the filing.
Outlook, Risks and Unusual Items
Management’s forward-looking statements include the expected timing and completion of the offering, expected proceeds and intended use of proceeds. These matters remain dependent on closing conditions and other risks.
- Key operating risks include development and commercial feasibility of the Nanox imaging system, regulatory clearances for Nanox.ARC and Nanox.CLOUD, manufacturing and supplier arrangements, market acceptance of the pay-per-scan model, global operations and competition.
- Material legal and financial risks include the unresolved SEC investigation, potential SEC remedies, the $8 million shareholder settlement, related litigation costs and possible additional claims.
- The filing also cites macroeconomic, political, regulatory, business-interruption and public-health risks.
Investor Verification Checklist
- Verify whether the registered direct offering closed as expected and the actual net proceeds received.
- Confirm the final warrant terms, registration status and any subsequent warrant exercises.
- Review the company’s later filings for the final SEC settlement, including approved penalties and payment timing.
- Confirm court approval and funding of the $8 million shareholder litigation settlement.
- Review subsequent financial statements for the impact of the offering, litigation obligations and available liquidity.
- Assess regulatory progress, commercialization, manufacturing capacity and customer adoption of Nanox.ARC and Nanox.CLOUD.